middle.news
Immuron Navigates FDA Review Amid Travelan® Trial Delay
9:33am on Friday 31st of October, 2025 AEDT
•
Biotechnology
Read Story
Immuron Navigates FDA Review Amid Travelan® Trial Delay
9:33am on Friday 31st of October, 2025 AEDT
Key Points
IMM-529 IND application under active FDA review with additional information submitted
Travelan® Uniformed Services University P2TD study topline data delayed to November
P2TD study results to influence dosing strategy for upcoming FDA End-of-Phase 2 meeting
Previous Travelan® trials show significant protection against travelers’ diarrhea
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMC
OPEN ARTICLE